• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Moonlake Reveals Phase 3 Sonelokimab Trial Results

    GLOBENEWSWIRE

    Moonlake Arthritis Win Kicks Off Pivotal Year For IL-17 Nanobody

    FIERCE BIOTECH

    Moonlake Reports Positive Phase 2 Trial Results For Sonelokimab

    GLOBENEWSWIRE

    FDA Fast-Track MoonLake`s Sonelokimab for Palmoplantar Pustulosis

    GLOBENEWSWIRE

    Moonlake Immunotherapeutics Reports Favorable Type B Meeting

    GLOBENEWSWIRE

    Moonlake Immunotherapeutics Prices $75M Offering

    GLOBENEWSWIRE

    Moonlake Immunotherapeutics Unveils Q3 2025 Financials Update

    GLOBENEWSWIRE

    MoonLake`s Stock Crashes After Eclipses Il-17 Drug`s Phase 3

    PRESS RELEASE

    Moon Lake Immunotherapeutics Reports Q2 2025 Results and Updates

    GLOBENEWSWIRE

    Merck made $3B offer for MoonLake & could revive interest

    FINANCIALTIMES

    MoonLake Immunotherapeutics Q1 2025 Financial Results & Business

    GLOBENEWSWIRE

    MoonLake Immunotherapeutics to host Capital Markets Day on April

    GLOBENEWSWIRE

    MoonLake Immunotherapeutics Reports 2024 Financial Results

    GLOBENEWSWIRE

    MoonLake Launches Three New Trials For Nanobody Sonelokimab

    GLOBENEWSWIRE

    MoonLake Starts Phase 3 IZAR Program of Sonelokimab in PsA

    GLOBENEWSWIRE

    MoonLake Immunotherapeutics Q3 2024 Results & Business Update

    GLOBENEWSWIRE

    MoonLake To Host Capital Markets Update September 11

    GLOBENEWSWIRE

    MoonLake Reports Q2 2024 Results, Announces September 11 Market Update

    GLOBENEWSWIRE

    MoonLake Gets Regulatory Feedback On Sonelokimab Phase 3 For Psoriatic Arthritis

    GLOBENEWSWIRE

    MoonLake Starts Sonelokimab Phase 3 In Hidradenitis Suppurativa

    GLOBENEWSWIRE

    MoonLake announces significant improvements with Nanobody® sonelokimab

    GLOBENEWSWIRE

    MoonLake announces landmark Phase 2 results for Nanobody sonelokimab

    GLOBENEWSWIRE

    Phase 2 MIRA primary analysis trial results for MoonLake`s Nanobody sonelokimab

    GLOBENEWSWIRE

    MoonLake achieves landmark milestone +ve Ph2 results for Nanobody® sonelokimab

    GLOBENEWSWIRE

    MoonLake completes patient enrollment in PII trial of the Nanobody sonelokimab

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.